comparemela.com
Home
Live Updates
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States : comparemela.com
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this weekEffective, safe, and very well-tolerated steroid-free foam provides...
Related Keywords
United States ,
Chicago ,
Illinois ,
Derek Cole ,
Amanda Sheldon ,
Todd Edwards ,
Raj Chovatiya ,
Exchange Commission ,
Arcutis Biotherapeutics Inc ,
Facebook ,
Savings Card Program ,
Nasdaq ,
Company Investor ,
Drug Administration ,
Head Of Corporate Communications ,
Investor Relations Advisory Solutions ,
Direct Program ,
Private Securities Litigation Reform Act ,
Markets ,
comparemela.com © 2020. All Rights Reserved.